Caris Life Sciences, Inc.
Caris Life Sciences, Inc.
Your view on CAI
Overview
What the company does, where it operates, and who runs it.
About Caris Life Sciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Dean Halbert
- Headquarters
- 750 West John Carpenter Freeway, Irving, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Dean Halbert
- Headquarters
- 750 West John Carpenter Freeway, Irving, TX, US
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms.
The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment.
It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Caris Life Sciences, Inc., and the rating behind it. CAI last traded at $24.34, 65.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Caris Life Sciences, Inc.. Starting points for Caris Life Sciences, Inc.: P/E 65.8, EPS $0.37, beta 0.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Caris Life Sciences, Inc.. Caris Life Sciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Caris Life Sciences, Inc.. Trailing twelve-month EPS for Caris Life Sciences, Inc. stands at $0.37. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Caris Life Sciences, Inc.. Caris Life Sciences, Inc. has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Caris Life Sciences, Inc. valued side by side against its closest peers. Caris Life Sciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Caris Life Sciences, Inc., and how their positions are changing. At a $6.88B market value, institutional positions materially move Caris Life Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Caris Life Sciences, Inc. executives and directors. Shares of Caris Life Sciences, Inc. have traded between $22.86 and $42.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Caris Life Sciences, Inc.. Caris Life Sciences, Inc. is a $6.88B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Caris Life Sciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Caris Life Sciences, Inc.. Coverage tracks Caris Life Sciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.